Protopanaxadiol as a Dual-Action Therapeutic Agent: Enhancing Radiotherapy Efficacy and Mitigating DMBA-Induced...

Area of Science:

• Pharmacology and Oncology
• Molecular Biology
• Radiotherapy Research

Background:

• Breast cancer is a leading cause of cancer mortality, with radiotherapy efficacy often limited by tumor resistance and systemic toxicity.
• Protopanaxadiol (PPD), a ginsenoside metabolite, exhibits potential as an adjunct therapy due to its diverse pharmacological properties.
• This study investigates PPD's dual role in enhancing radiosensitivity and providing cytoprotection in breast cancer.

Purpose of the Study:

• To evaluate Protopanaxadiol's (PPD) efficacy as a radiosensitizer and cytoprotective agent in breast cancer.
• To elucidate the underlying mechanisms of PPD's action using in vitro, in vivo, and in silico models.
• To assess PPD's impact on tumor cell cycle, apoptosis, oxidative stress, and key molecular pathways.

Main Methods:

• In vitro studies utilized MCF-7 cells to assess PPD's cytotoxicity and cell cycle effects in combination with gamma irradiation.
• In vivo efficacy was evaluated in a DMBA-induced breast cancer mouse model, analyzing hematological, lipid, oxidative stress, and apoptotic markers.
• Molecular docking and ADMET analysis were employed to predict PPD's binding affinities to target proteins and its pharmacokinetic properties.

Main Results:

• PPD significantly enhanced gamma irradiation's cytotoxicity and induced cell cycle arrest.
• In vivo, PPD improved hematological and lipid profiles, mitigated oxidative stress, and modulated apoptotic markers and gene expression (HIF-1α, NF-κB, PHD2).
• Molecular docking indicated strong binding affinities for PPD to HIF-1α, NF-κB, and PHD2, with favorable ADMET profiling.

Conclusions:

• PPD demonstrates multimodal anti-cancer effects, enhancing radiosensitivity and rebalancing oxidative status, hypoxia, and inflammation.
• PPD's favorable molecular interactions and pharmacokinetic profile suggest significant clinical potential as an adjunct breast cancer therapy.
• Further clinical studies are warranted to explore PPD's therapeutic benefits in breast cancer treatment.